December, 2005 (2)

• Evaluation of a clinical screening tool for HIV-associated sensory neuropathies.
  Cherry CL, Wesselingh SL, Lal L, McArthur JC
  Neurology. 2005 Dec; 65(11):1778-1781
• Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.
  Jennings C, Fiscus SA, Crowe SM, Danilovic AD, Morack RJ, Scianna S, Cachafeiro A, Brambilla DJ, Schupbach J, Stevens W, Respess R, Varnier OE, Corrigan GE, Gronowitz JS, Ussery MA, Bremer JW
  J Clin Microbiol. 2005 Dec; 43(12):5950-5956

November, 2005 (1)

• Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
  Emery S, Workman C, Puls RL, Bloch M, Baker D, Bodsworth N, Anderson J, Crowe SM, French MAH, Hoy J, Aichelburg A, Ward LD, Boyle DB, Law MG, Kelleher AD, Cooper DA
  Hum Vaccin. 2005 Nov; 1(6):232-238

October, 2005 (3)

• Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts.
  Solomon A, Lane N, Wightman F, Gorry PR, Lewin SR
  J Acquir Immune Defic Syndr. 2005 Oct; 40(2):140-148
• Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response.
  Ong CL, Thorpe JC, Gorry PR, Bannwarth S, Jaworowski A, Howard JL, Chung S, Campbell S, Christensen HS, Clerzius G, Mouland AJ, Gatignol A, Purcell DFJ
  J Virol. 2005 Oct; 79(20):12763-12772
• Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection.
  Maslin CLV, Kedzierska K, Webster NL, Muller WA, Crowe SM
  Curr HIV Res. 2005 Oct; 3(4):303-317

September, 2005 (2)

• Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
  Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Gao K, Medveckzy J, Ffrench RA, Ramshaw IA
  Vaccine. 2005 Sep; 23(38):4647-4657
• HIV-related knowledge, attitudes and risk perception amongst nurses, doctors and other healthcare workers in rural India.
  Kermode M, Holmes W, Lagkham B, Thomas MS, Gifford S
  Indian J Med Res. 2005 Sep; 122(3):258-264

August, 2005 (1)

• Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.
  Wapling J, Moore KL, Sonza S, Mak J, Tachedjian G
  J Virol. 2005 Aug; 79(16):10247-10257

July, 2005 (2)

• Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.
  Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, Crowe SM, Wesselingh SL, Cunningham AL, Gorry PR
  Virology. 2005 Jul; 337(2):384-398
• Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase.
  Tachedjian G, Radzio J, Sluis-Cremer N
  Proteins. 2005 Jul; 60(1):5-13

June, 2005 (2)

• Is there a role for plant-made vaccines in the prevention of HIV/AIDS?
  Webster DE, Thomas MC, Pickering R, Whyte A, Dry IB, Gorry PR, Wesselingh SL
  Immunol Cell Biol. 2005 Jun; 83(3):239-247
• Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.
  Cook JE, Dasgupta S, Middaugh LD, Terry EC, Gorry PR, Wesselingh SL, Tyor WR
  Ann Neurol. 2005 Jun; 57(6):795-803

May, 2005 (2)

• In vivo replication kinetics of a nef-deleted strain of HIV-1.
  Crowe SM, Ho DD, Marriott D, Brew B, Gorry PR, Sullivan JS, Learmont J, Mills J
  AIDS. 2005 May; 19(8):842-843
• Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation.
  Buxton P, Tachedjian G, Mak J
  J Virol. 2005 May; 79(10):6338-6348

April, 2005 (2)

• Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring.
  Greengrass VL, Turnbulll SP, Hocking J, Dunne AL, Tachedjian G, Corrigan GE, Crowe SM
  Curr HIV Res. 2005 Apr; 3(2):183-190
• Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay.
  Guy RJ, Breschkin AM, Keenan CM, Catton MG, Enriquez AM, Hellard ME
  J Acquir Immune Defic Syndr. 2005 Apr; 38(4):495-499

March, 2005 (1)

• Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to Abacavir or Zidovudine.
  Cherry CL, Lal L, Thompson KA, McLean CA, Ross LL, Hernandez J, Wesselingh SL, McComsey G
  J Acquir Immune Defic Syndr. 2005 Mar; 38(3):263-267

January, 2005 (9)

• Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
  Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N
  FEBS Lett. 2005 Jan; 579(2):379-384
• Improvements in Lipoatrophy, Mitochondrial DNA Content amd Adipose Tissue Apoptosis Levels after Replacement of Stavudine with Abacavir or Zidovudine.
  McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, Ross LL
  AIDS. 2005 Jan; 19(1):15-23
• The packaging and maturation of the HIV-1 Pol proteins.
  Hill M, Tachedjian G, Mak J
  Curr HIV Res. 2005 Jan; 3(1):73-85
• Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring and management.
  Cherry CL, Lala L, Wesselingh SL
  Sex Health. 2005 Jan; 2(1):1-11
• Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
  Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K
  Curr Med Chem. 2005 Jan; 12(15):1705-1719
• Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users.
  Needle RH, Burrows D, Friedman SR, Dorabjee J, Touze G, Badrieva L, Grund JPC, Kumar MS, Nigro L, Manning G, Latkin C
  Int J Drug Pol. 2005 Jan; 16:S45-57
• Pathogenesis of macrophage tropic HIV-1.
  Gorry PR, Churchill M, Crowe SM, Cunningham AL, Gabuzda D
  Curr HIV Res. 2005 Jan; 3(1):53-60
• Isolation of human immunodeficiency virus type 1 from peripheral blood monocytes.
  Gorry PR, Sonza S, Kedzierska K, Crowe SM
  Methods Mol Biol. 2005 Jan; 304:25-33
• Phenotypic characterization of blood monocytes from HIV-infected individuals.
  Ellery PJ, Crowe SM
  Methods Mol Biol. 2005 Jan; 304:343-353